PD53 - Budesonide therapy reduces sCD30-levels in atopic infants with recurrent respiratory symptoms
© Kotaniemi-Syrjänen et al; licensee BioMed Central Ltd. 2014
Published: 28 February 2014
Only minority of infants with recurrent or persistent respiratory symptoms will develop asthma. The development of asthma is associated with Th1- and Th2-cell activity imbalance. Increased levels of Th1 activation marker, serum soluble CD26 (sCD26), and Th2 activation marker, serum soluble CD30 (sCD30) have been found in asthmatic adults and school children. Whether these markers are of clinical use in infants with troublesome lung symptoms has not been evaluated before.
In conclusion, Th1-type immunity is suppressed and Th2-type immunity activated in infants with troublesome lung symptoms. However, only atopic infants may benefit of anti-inflammatory inhalants.
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.